D
Teva Pharmaceutical Industries Limited TEVA
$33.92 -$0.39-1.14% NYSE
Recommendation
Dividend Power Score
Prev Close
$34.31
Volume
6,025,549
Avg Vol (90D)
10,791,107
Market Cap
$39.96B
Dividend & Yield
--
52-Week Range
$12.47 - $37.35
P/E (TTM)
28.63
EPS (TTM)
$1.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
MarketBeat Week in Review – 02/03 - 02/07
2/8/2025 - MarketBeat
Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift What's Changed
2/11/2026 - Simply Wall St
Noteworthy ETF Inflows: SPDW, SPOT, SE, TEVA
2/11/2026 - ETF Channel
Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings
2/10/2026 - Yahoo! Finance: News
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes
2/10/2026 - Simply Wall St
The Goldman Sachs Group Increases Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $45.00
2/9/2026 - MarketBeat
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
2/9/2026 - Zacks Investment Research
12 Best Healthcare Stocks Under $50 to Invest In
2/9/2026 - Insider Monkey
Goldman Sachs Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)
2/9/2026 - TipRanks Financial Blog
Allianz Asset Management GmbH Sells 69,654 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
2/9/2026 - MarketBeat
Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by BI Asset Management Fondsmaeglerselskab A S
2/8/2026 - MarketBeat
Thrivent Financial for Lutherans Buys Shares of 199,467 Teva Pharmaceutical Industries Ltd. $TEVA
2/8/2026 - MarketBeat
Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential?
2/6/2026 - Insider Monkey
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat
2/4/2026 - Yahoo! Finance: News
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
2/4/2026 - CNW Group - News Releases
Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by WCM Investment Management LLC
2/4/2026 - MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High - What's Next?
2/4/2026 - MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 12-Month High - Should You Buy?
2/4/2026 - Ticker Report
Teva's Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands
2/4/2026 - TipRanks Financial Blog
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
2/4/2026 - Insider Monkey
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate
2/3/2026 - Simply Wall St
11 Cheap Hot Stocks to Invest In Right Now
2/3/2026 - Insider Monkey
Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA
2/3/2026 - ETF Channel
National Pension Service Raises Holdings in Teva Pharmaceutical Industries Ltd. $TEVA
2/3/2026 - MarketBeat
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
2/3/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$17.26B
EBITDA (TTM)
$4.96B
EBIT (TTM)
$3.95B
Net Income (TTM)
$1.41B
Balance Sheet
Total Assets (Q)
$40.75B
Total Debt (Q)
$17.23B
Total Liabilities (Q)
$32.83B
Book Value Per Share (Q)
$6.88
Cash Flow
Cash from Operations (TTM)
$1.65B
Cash from Investing (TTM)
$737.00M
Cash from Financing (TTM)
-$2.15B
Net Change in Cash (TTM)
$256.00M
Filings
Filing Date
Tuesday, February 3, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Loading...
Beta
0.64
7-Day Total Return
-6.43%
30-Day Total Return
8.23%
60-Day Total Return
33.49%
90-Day Total Return
69.52%
Year to Date Total Return
9.60%
1-Year Total Return
107.59%
2-Year Total Return
162.74%
3-Year Total Return
229.32%
5-Year Total Return
205.04%
52-week Low
Apr 10, 2025 - $12.47
52-week High
Feb 03, 2026 - $37.35
Valuation
Market Cap
$39.96B - Large Cap
Enterprise Value
$53.64B
Price/Sales (TTM)
2.33
Price/Book (Q)
4.99
Dividends and Shares
Shares Outstanding
1.17B
Dividend Per Share (Most Recent)
$0.07
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tevapharm.com
Phone Number
972 3 914 8213
Address
124 Dvora HaNevi’a St.
Tel Aviv-Yafo, 6944020
Country
Israel
Year Founded
1901
Business Description
Sector
--
Industry
--
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and... more
NYSE 02/12/2026 4:00PM Eastern Quotes delayed